ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
A Study on the Correlation Between Visceral Adiposity Index, Fatty Liver Index, and Thyroid Dysfunction in Patients with Type 2 Diabetes Mellitus.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study explores the correlations between visceral adiposity index, fatty liver indices and thyroid dysfunction in type 2 diabetes mellitus patients. Methods: This cross-sectional investigation was carried out between January 2021 and December 2022, encompassing 131 adult out-patients. Patients with other endocrine diseases, severe hepatic or renal insufficiency, or recent use of thyroid-affecting medications were excluded. Clinical and laboratory data, including body mass index, waist circumference, lipid profiles, liver function markers, and thyroid function tests, were collected. Results: Blood tests showed hepatic injury markers, alanine aminotransferase, aspartate aminotransferase, and adverse lipid profiles, elevated triglycerides, reduced high-density lipoprotein, significantly increased across fatty liver indices quartiles (P < 0.05), reflecting hepatocellular injury. Waist circumference and body mass index also increased significantly with higher fatty liver indices quartiles. Similarly, visceral adiposity index showed strong correlations with metabolic parameters, including elevated alanine aminotransferase, aspartate aminotransferase, and triglycerides levels (P < 0.05). Regarding thyroid function, TSH levels increased to some extent (P = 0.068), suggesting a potential link between fatty liver and hypothyroidism. Conclusion: This study highlights the significant role of visceral fat accumulation and liver fat deposition in contributing to insulin resistance and metabolic imbalances among individuals with type 2 diabetes. Clinicians and public health departments should promote early identification and intervention of visceral fat accumulation and fatty liver as tools to prevent metabolic syndrome and related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.